Jump to content

Talk:Ingenol mebutate

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia
[edit]

The European Medicines Agency recommended suspending the marketing authorisation of ingenol mebutate due to concerns regarding increased incidence of skin cancer in patients treated with topical ingenol mebutate compared to vehicle or imiquimod. — Preceding unsigned comment added by 2600:6C50:97F:ED38:200A:FBE5:B7DD:9DEF (talk) 22:37, 19 February 2021 (UTC)[reply]